NCT07664735尚未招募1 期
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.
详细描述
A phase 1a/b study to evaluate the safety and efficacy of OPB-201, an autologous PReferentially expressed Antigen of MElanoma (PRAME) T cell receptor (TCR) T cell therapy in recurrent endometrial and platinum-resistant ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of age at the time of signing the informed consent form.
- •Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
- •Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.
- •Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
- •Measurable disease.
- •Consent to provide archived tumor tissue sample.
- •ECOG performance status of 0 or
- •Adequate organ function.
- •HLA-A *02:01 or HLA-A *02:02
- •PRAME positive tumor
排除标准
- •Women of child-bearing potential who are pregnant or breastfeeding.
- •Uncontrolled bacterial, fungal, or viral infections.
- •Active infection requiring systemic therapy.
- •Bleeding or thrombotic disorders or at risk for severe hemorrhage.
- •Any form of primary immunodeficiency.
- •Had an allogenic tissue/solid organ transplant.
- •Active autoimmune disease.
- •Concurrent treatment with systemic high dose corticosteroids.
- •Unresolved acute effects of any prior therapy.
- •Other exclusions as stated in the protocol.
研究者
相似试验
招募中
2 期
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCHCC - Hepatocellular CarcinomaNCT07521852TaiRx, Inc.40
招募中
1 期
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab ImmunotherapyRectal CancerNCT07561060Fudan University50
Enrolling By Invitation
1 期
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCBladder Urothelial CarcinomaLymph Node MetastasisNCT07353294Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University12
尚未招募
1 期
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNCT07398638Sun Yat-sen University122
尚未招募
1 期
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaRelapsed/Refractory B-cell LymphomaDiffuse Large B-cell LymphomaInert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)NCT07539688Institute of Hematology & Blood Diseases Hospital, China18